Events Partner Content 2nd Gene Therapy for Blood Disorders Gene Therapy for Blood Disorders Digital Summit
News Breakthrough status for BioMarin ratchets up haemophilia A c... The FDA has granted Breakthrough Therapy Designation to BioMarin’s gene therapy for haemophilia A, helping to intensify competition in the field.
News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News CAR-Ts to take centre stage at ASH haematology congress Haematology is one of the most exciting areas in drug development today, with waves of new treatments emerging for hard-to-treat diseases.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
